Four single nucleotide polymorphisms in genes involved in neuronal signaling are associated with opioid use disorder in West Virginia


  • Shane W. Kaski, BS, MD/PhD
  • Stephan Brooks, MPH
  • Sijin Wen, PhD
  • Marc W. Haut, PhD
  • David P. Siderovski, PhD
  • James H. Berry, DO
  • Laura R. Lander, MSW
  • Vincent Setola, PhD



opioid use disorder (OUD), substance use disorder (SUD), single nucleotide polymorphisms (SNPs), genetic testing


Objective: Pilot study to assess utility in opioid use disorder (OUD) of a panel of single nucleotide polymorphisms (SNPs) in genes previously related to substance use disorder (SUD) and/or phenotypes that predispose individuals to OUD/SUD.

Design: Genetic association study.

Setting: West Virginia University’s Chestnut Ridge Center Comprehensive Opioid Addiction Treatment (COAT) clinic for individuals diagnosed with OUD.

Patients: Sixty patients 18 years of age or older with OUD undergoing medication (buprenorphine/naloxone)-assisted treatment; all 60 patients recruited contributed samples for genetic analysis.

Outcome measure(s): Minor allele frequencies for SNPs.

Results: Four of the 14 SNPs examined were present at frequencies that are statistically significantly different than in a demographically matched general population.

Conclusions: For the purposes of testing WV individuals via genetic means for predisposition to OUD, at least four SNPs in three genes are likely to have utility in predicting susceptibility. Additional studies with larger populations will need to be conducted to confirm these results before use in a clinical setting.

Author Biographies

Shane W. Kaski, BS, MD/PhD

Dual Degree Scholar, Department of Physiology & Pharmacology, West Virginia University School of Medicine, Morgantown, West Virginia

Stephan Brooks, MPH

Coordinator, Clarion University of Pennsylvania, Clarion, Pennsylvania

Sijin Wen, PhD

Associate Professor, Department of Biostatistics, West Virginia University School of Public Health, Morgantown, West Virginia

Marc W. Haut, PhD

Professor and Chair, Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine, Morgantown, West Virginia

David P. Siderovski, PhD

Professor and Chair, Department of Physiology & Pharmacology, West Virginia University School of Medicine, Morgantown, West Virginia

James H. Berry, DO

Associate Professor, Medical Director, Chestnut Ridge Center and Inpatient Acute Dual Diagnosis Program, West Virginia University School of Medicine, Morgantown, West Virginia

Laura R. Lander, MSW

Associate Professor, West Virginia University School of Medicine, Morgantown, West Virginia

Vincent Setola, PhD

Assistant Professor, Department of Behavioral Medicine and Psychiatry; Department of Neuroscience; and Department of Physiology & Pharmacology, West Virginia University School of Medicine, Morgantown, West Virginia


Rudd RA, Seth P, David F, et al.: Increases in drug and opioid-involved overdose deaths—United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016; 65(5051): 1445-1452.

McBain R, Rose AJ, LaRochelle MR: The U.S. opioid epidemic: One disease, diverging tales. Prev Med. 2018; 112: 176-178.

Fischer B, Keates A, Buhringer G, et al.: Non-medical use of prescription opioids and prescription opioid-related harms: Why so markedly higher in North America compared to the rest of the world? Addiction. 2014; 109(2): 177-181.

Jordan AE, Blackburn NA, Des Jarlais DC, et al.: Past-year prevalence of prescription opioid misuse among those 11 to 30 years of age in the United States: A systematic review and metaanalysis. J Subst Abuse Treat. 2017; 77: 31-37.

Pergolizzi JV Jr, LeQuang JA, Taylor R Jr, et al.: Going beyond prescription pain relievers to understand the opioid epidemic: The role of illicit fentanyl, new psychoactive substances, and street heroin. Postgrad Med. 2018; 130(1): 1-8.

Dowell D, Arias E, Kochanek K, et al.: Contribution of opioid-involved poisoning to the change in life expectancy in the United States, 2000-2015. JAMA. 2017; 318(11): 1065-1067.

Marshalek PJ, Sullivan CR: Buprenorphine clinics: An integrated and multidisciplinary approach to treating opioid dependence. W V Med J. 2010; 106(4 Spec No): 60-63.

Schmid CL, Kennedy NM, Ross NC, et al.: Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell. 2017; 171(5): 1165-1175.e13.

Vashishtha D, Mittal ML, Werb D: The North American opioid epidemic: Current challenges and a call for treatment as prevention. Harm Reduct J. 2017; 14(1): 7.

Ratycz MC, Papadimos TJ, Vanderbilt AA: Addressing the growing opioid and heroin abuse epidemic: A call for medical school curricula. Med Educ Online. 2018; 23(1): 1466574.

Blum K, Chen ALC, Thanos PK, et al.: Genetic addiction risk score (GARS), a predictor of vulnerability to opioid dependence. Front Biosci (Elite Ed). 2018; 10: 175-196.

Kreek MJ, Levran O, Reed B, et al.: Opiate addiction and cocaine addiction: Underlying molecular neurobiology and genetics. J Clin Invest. 2012; 122(10): 3387-3393.

Bawor M, Dennis BB, Tan C, et al.: Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: An observational study. Addict Sci Clin Pract. 2015; 10: 19.

Curtis K, Viswanath H, Velasquez KM, et al.: Increased habenular connectivity in opioid users is associated with an α5 subunit nicotinic receptor genetic variant. Am J Addict. 2017; 26(7): 751-759.

Crist RC, Clarke TK, Berrettini WH: Pharmacogenetics of opioid use disorder treatment. CNS Drugs. 2018; 32(4): 305-320.

Fonseca F, Torrens M: Pharmacogenetics of methadone response. Mol Diagn Ther. 2018; 22(1): 57-78.

Mistry CJ, Bawor M, Desai D, et al.: Genetics of opioid dependence: A review of the genetic contribution to opioid dependence. Curr Psychiatry Rev. 2014; 10(2): 156-167.

Nielsen DA, Kreek MJ: Common and specific liability to addiction: Approaches to association studies of opioid addiction. Drug Alcohol Depend. 2012; 123(suppl 1): S33-S41.

Lu L, Shepard JD, Hall FS, et al.: Effect of environmental stressors on opiate and psychostimulant reinforcement, reinstatement and discrimination in rats: A review. Neurosci Biobehav Rev. 2003; 27(5): 457-491.

Badiani A, Robinson TE: Drug-induced neurobehavioral plasticity: The role of environmental context. Behav Pharmacol. 2004; 15(5-6): 327-339.

Scherbaum N, Specka M: Factors influencing the course of opiate addiction. Int J Methods Psychiatr Res. 2008; 17(suppl 1): S39-S44.

Valentine K, Fraser S: Trauma, damage and pleasure: Rethinking problematic drug use. Int J Drug Policy. 2008; 19(5): 410-416.

Ducci F, Goldman D: The genetic basis of addictive disorders. Psychiatr Clin North Am. 2012; 35(2): 495-519.

McCarberg B: Tramadol extended-release in the management of chronic pain. Ther Clin Risk Manag. 2007; 3(3): 401-410.

Smith HS, Raffa RB, Pergolizzi JV, et al.: Combining opioid and adrenergic mechanisms for chronic pain. Postgrad Med. 2014; 126(4): 98-114.

Seth P, Scholl L, Rudd RA, et al.: Overdose deaths involving opioids, cocaine, and psychostimulants - United States, 2015-2016. MMWR Morb Mortal Wkly Rep. 2018; 67(12): 349-358.

Gall BJ, Wilson A, Schroer AB, et al.: Genetic variations in GPSM3 associated with protection from rheumatoid arthritis affect its transcript abundance. Genes Immun. 2016; 17(2): 139-147.

Tincher RB: Night comes to the chromosomes: Inbreeding and population genetics in southern Appalachia. Cent Issues Anthropol. 1980; 2(1): 27-49.

Lander LR, Marshalek P, Yitayew M, et al.: Rural healthcare disparities: Challenges and solutions for the pregnant opioid-dependent population. W V Med J. 2013; 109(4): 22-27.

Zheng WH, Wakim RJ, Geary RC, et al.: Self-reported sleep improvement in buprenorphine MAT (medication assisted treatment) population. Austin J Drug Abuse Addict. 2016; 3(1): 1009.

Zheng W, Nickasch M, Lander L, et al.: Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder: A 2-year retrospective data analysis. J Addict Med. 2017; 11(2): 138-144.

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association Publishing, 2013.

1000 Genomes Project Consortium, Auton A, Brooks LD, et al.: A global reference for human genetic variation. Nature. 2015; 526(7571): 68-74.

Song W, Gardner SA, Hovhannisyan H, et al.: Exploring the landscape of pathogenic genetic variation in the ExAC population database: Insights of relevance to variant classification. Genet Med. 2016; 18(8): 850-854.

Blomqvist O, Gelernter J, Kranzler HR: Family-based study of DRD2 alleles in alcohol and drug dependence. Am J Med Genet. 2000; 96(5): 659-664.

Ikeda M, Yamanouchi Y, Kinoshita Y, et al.: Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics. 2008; 9(10): 1437-1443.

Doly S, Valjent E, Setola V, et al.: Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamineinduced hyperlocomotion and 5-HT release in vivo and in vitro. J Neurosci. 2008; 28(11): 2933-2940.

Doly S, Bertran-Gonzalez J, Callebert J, et al.: Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice. PLoS One. 2009; 4(11): e7952.

Lin Z, Walther D, Yu XY, et al.: The human serotonin receptor 2B: Coding region polymorphisms and association with vulnerability to illegal drug abuse. Pharmacogenetics. 2004; 14(12): 805-811.

Beer B, Erb R, Pavlic M, et al.: Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: A case-control study. PLoS One. 2013; 8(9): e75359.

Xu J, Lu Z, Xu M, et al.: A heroin addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA splicing of the mu opioid receptor gene OPRM1 via hnRNPH interactions. J Neurosci. 2014; 34(33): 11048-11066.

Olesen AE, Sato H, Nielsen LM, et al.: The genetic influences on oxycodone response characteristics in human experimental pain. Fundam Clin Pharmacol. 2015; 29(4): 417-425.

Adrian M, Kiff C, Glazner C, et al.: Examining gene-environment interactions in comorbid depressive and disruptive behavior disorders using a Bayesian approach. J Psychiatr Res. 2015; 68: 125-133.

Bartosova O, Polanecky O, Perlik F, et al.: OPRM1 and ABCB1 polymorphisms and their effect on postoperative pain relief with piritramide. Physiol Res. 2015; 64(suppl 4): S521-S527.

Laugsand EA, Skorpen F, Kaasa S, et al.: Genetic and nongenetic factors associated with constipation in cancer patients receiving opioids. Clin Transl Gastroenterol. 2015; 6: e90.

Wachman EM, Hayes MJ, Sherva R, et al.: Variations in opioid receptor genes in neonatal abstinence syndrome. Drug Alcohol Depend. 2015; 155: 253-259.

Woodcock EA, Lundahl LH, Burmeister M, et al.: Functional mu opioid receptor polymorphism (OPRM1 A(118) G) associated with heroin use outcomes in Caucasian males: A pilot study. Am J Addict. 2015; 24(4): 329-335.

Matic M, van den Bosch GE, de Wildt SN, et al.: Genetic variants associated with thermal pain sensitivity in a paediatric population. Pain. 2016; 157(11): 2476-2482.

Schwantes-An TH, Zhang J, Chen LS, et al.: Association of the OPRM1 variant rs1799971 (A118G) with non-specific liability to substance dependence in a collaborative de novo metaanalysis of European-ancestry cohorts. Behav Genet. 2016; 46(2): 151-169.

Choi SW, Lam DMH, Wong SSC, et al.: Effects of single nucleotide polymorphisms on surgical and postsurgical opioid requirements: A systematic review and meta-analysis. Clin J Pain. 2017; 33(12): 1117-1130.

Gao X, Wang Y, Lang M, et al.: Contribution of genetic polymorphisms and haplotypes in DRD2, BDNF, and opioid receptors to heroin dependence and endophenotypes among the Han Chinese. OMICS. 2017; 21(7): 404-412.

Levran O, Peles E, Randesi M, et al.: The mu-opioid receptor nonsynonymous variant 118A>G is associated with prolonged abstinence from heroin without agonist treatment. Pharmacogenomics. 2017; 18(15): 1387-1391.

Gong XD, Wang JY, Liu F, et al.: Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain. Asian Pac J Cancer Prev. 2013; 14(5): 2937-2943.

Haerian BS, Haerian MS: OPRM1 rs1799971 polymorphism and opioid dependence: Evidence from a meta-analysis. Pharmacogenomics. 2013; 14(7): 813-824.

Kolesnikov Y, Gabovits B, Levin A, et al.: Chronic pain after lower abdominal surgery: Do catechol-O-methyl transferase/opioid receptor mu-1 polymorphisms contribute? Mol Pain. 2013; 9: 19.

Manini AF, Jacobs MM, Vlahov D, et al.: Opioid receptor polymorphism A118G associated with clinical severity in a drug overdose population. J Med Toxicol. 2013; 9(2): 148-154.

Song Z, Du B, Wang K, et al.: Effects of OPRM1 A118G polymorphism on epidural analgesia with fentanyl during labor: A meta-analysis. Genet Test Mol Biomarkers. 2013; 17(10): 743-749.

Cajanus K, Kaunisto MA, Tallgren M, et al.: How much oxycodone is needed for adequate analgesia after breast cancer surgery: Effect of the OPRM1 118A>G polymorphism. J Pain. 2014; 15(12): 1248-1256.

Solak O, Erdogan MO, Yildiz H, et al.: Assessment of opioid receptor μ1 gene A118G polymorphism and its association with pain intensity in patients with fibromyalgia. Rheumatol Int. 2014; 34(9): 1257-1261.

Hancock DB, Levy JL, Gaddis NC, et al.: Cis-expression quantitative trait loci mapping reveals replicable associations with heroin addiction in OPRM1. Biol Psychiatry. 2015; 78(7): 474-484.

Pfeifer P, Sariyar M, Eggermann T, et al.: Alcohol consumption in healthy OPRM1 G allele carriers and its association with impulsive behavior. Alcohol Alcohol. 2015; 50(4): 379-384.

Oertel BG, Doehring A, Roskam B, et al.: Genetic-epigenetic interaction modulates μ-opioid receptor regulation. Hum Mol Genet. 2012; 21(21): 4751-4760.

Carpentier PJ, Arias Vasquez A, Hoogman M, et al.: Shared and unique genetic contributions to attention deficit/hyperactivity disorder and substance use disorders: A pilot study of six candidate genes. Eur Neuropsychopharmacol. 2013; 23(6): 448-457.

Smoller JW, Paulus MP, Fagerness JA, et al.: Influence of RGS2 on anxiety-related temperament, personality, and brain function. Arch Gen Psychiatry. 2008; 65(3): 298-308.

Amstadter AB, Koenen KC, Ruggiero KJ, et al.: Variation in RGS2 is associated with suicidal ideation in an epidemiological study of adults exposed to the 2004 Florida hurricanes. Arch Suicide Res. 2009; 13(4): 349-357.

Koenen KC, Amstadter AB, Ruggiero KJ, et al.: RGS2 and generalized anxiety disorder in an epidemiologic sample of hurricane- exposed adults. Depress Anxiety. 2009; 26(4): 309-315.

Dunn EC, Solovieff N, Lowe SR, et al.: Interaction between genetic variants and exposure to hurricane Katrina on post-traumatic stress and post-traumatic growth: A prospective analysis of low income adults. J Affect Disord. 2014; 152-154: 243-249.

Stein MB, Keshaviah A, Haddad SA, et al.: Influence of RGS2 on sertraline treatment for social anxiety disorder. Neuropsychopharmacology. 2014; 39(6): 1340-1346.

Hohoff C, Weber H, Richter J, et al.: RGS2 ggenetic variation: Association analysis with panic disorder and dimensional as well as intermediate phenotypes of anxiety. Am J Med Genet B Neuropsychiatr Genet. 2015; 168B(3): 211-222.

Amstadter AB, Koenen KC, Ruggiero KJ, et al.: Variant in RGS2 moderates posttraumatic stress symptoms following potentially traumatic event exposure. J Anxiety Disord. 2009; 23(3): 369-373.

Zhang H, Wang F, Kranzler HR, et al.: Variation in regulator of G-protein signaling 17 gene (RGS17) is associated with multiple substance dependence diagnoses. Behav Brain Funct. 2012; 8: 23.

Egan MF, Kojima M, Callicott JH, et al.: The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003; 112(2): 257-269.

de Cid R, Fonseca F, Gratacos M, et al.: BDNF variability in opioid addicts and response to methadone treatment: Preliminary findings. Genes Brain Behav. 2008; 7(5): 515-522.

Nascimento FA, Andrade DM: Myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK) is caused by heterozygous KCNC1 mutations. Epileptic Disord. 2016; 18(S2): 135-138.

Pal A, Chakraborty J, Das S: Association of CREB1 gene polymorphism with drug seeking behaviour in eastern Indian addicts. Neurosci Lett. 2014; 570: 53-57.

Oliveira-Dos-Santos AJ, Matsumoto G, Snow BE, et al.: Regulation of T cell activation, anxiety, and male aggression by RGS2. Proc Natl Acad Sci U S A. 2000; 97(22): 12272-12277.

Siderovski DP, Willard FS: The GAPs, GEFs, and GDIs of heterotrimeric G-protein alpha subunits. Int J Biol Sci. 2005; 1(2): 51-66.

Ingi T, Krumins AM, Chidiac P, et al.: Dynamic regulation of RGS2 suggests a novel mechanism in G-protein signaling and neuronal plasticity. J Neurosci. 1998; 18(18): 7178-7188.

Kimple AJ, Soundararajan M, Hutsell SQ, et al.: Structural determinants of G-protein alpha subunit selectivity by regulator of G-protein signaling 2 (RGS2). J Biol Chem. 2009; 284(29): 19402-19411.

Doly S, Quentin E, Eddine R, et al.: Serotonin 2B receptors in mesoaccumbens dopamine pathway regulate cocaine responses. J Neurosci. 2017; 37(43): 10372-10388.

Bevilacqua L, Doly S, Kaprio J, et al.: A population-specific HTR2B stop codon predisposes to severe impulsivity. Nature. 2010; 468(7327): 1061-1066.

Diaz SL, Narboux-Neme N, Boutourlinsky K, et al.: Mice lacking the serotonin 5-HT2B receptor as an animal model of resistance to selective serotonin reuptake inhibitors antidepressants. Eur Neuropsychopharmacol. 2016; 26(2): 265-279.



How to Cite

Kaski, BS, MD/PhD, S. W., S. Brooks, MPH, S. Wen, PhD, M. W. Haut, PhD, D. P. Siderovski, PhD, J. H. Berry, DO, L. R. Lander, MSW, and V. Setola, PhD. “Four Single Nucleotide Polymorphisms in Genes Involved in Neuronal Signaling Are Associated With Opioid Use Disorder in West Virginia”. Journal of Opioid Management, vol. 15, no. 2, Mar. 2019, pp. 103-9, doi:10.5055/jom.2019.0491.



Brief Communication